The Goal of the SystHERs Registry
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses the goals of the SystHERs Registry.
Debu Tripathy, MD, co-leader, Women's Cancer Program, University of Southern California Norris Comprehensive Cancer Center, discusses the goals of the SystHERs Registry.
Clinical Pearls:
- This registry will enroll patients who have been diagnosed with HER2/neu-positive metastatic breast cancer within the last 6 months.
- The registry will collect detailed information on patients who are diagnosed with HER2 metastatic breast cancer to look both at the demographic factors as well as their past history.
- The registry will also look at what treatment they receive in the metastatic setting, what their outcomes are in terms of response and side effects.
- This will help researchers better understand how patients react to new agents that have been developed in this space.
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Dato-DXd Shows Promise as a More Tolerable ADC in HER2-Negative mBC
July 22nd 2024During a Case-Based Roundtable® event, Igor Makhlin, MD, discussed with participants their impressions of datopotamab deruxtecan as therapy for patients with HR-positive, HER2-negative breast cancer, and the sequential use of multiple antibody-drug conjugates.
Read More
